Hungarian-developed COVID-19 drug shows promise after tests
Photo by Planar/shutterstock.com. (For illustration purposes only)
A drug developed by a consortium of Hungarian researchers, including ones from Budapest's Eötvös Loránd University (ELTE) and pharmaceutical company Gedeon Richter, appears to be effective for the treatment of coronavirus based on animal tests, ELTE immunologist Imre Kacskovics, who heads the researchers, said on public radio on Tuesday, according to a report by Hungarian news agency MTI.
The animal tests show the drug not only inhibits infection by COVID-19 but alleviates symptoms after COVID-19 infection, Kacskovics said on Kossuth Rádió.
He added that the drug starts to work within 12 hours after it is injected.
The consortium developing the drug started its work in March.
Hungary Gasoline Prices 3% Over Regional Avg
Gov't Wants Sustainable Business Model for Magyar Posta
120,000 Guest Workers Employed in Hungary
Budapest Airport Wins 'Best Airport in Eastern Europe' for 1...
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
